Obudai Egeszseguegyi Centrum Kft.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Obudai Egeszseguegyi Centrum Kft. includes several studies aimed at reducing the risk of major heart events in patients with atherosclerotic cardiovascular disease and related conditions.
- Inclisiran to lower the incidence of major adverse cardiovascular events
- Maridebart Cafraglutide as an adjunct therapy for cardiovascular morbidity and mortality
- Olpasiran targeting lipoprotein(a) to prevent first major cardiovascular events
- AZD0780 evaluated for its impact on LDL‑C levels
- Baxdrostat combined with dapagliflozin to improve kidney‑cardio outcomes
These trials collectively explore innovative treatments to improve heart health and prevent complications such as heart attacks and strokes.
Digestive System Diseases
Studies at the centre focus on inflammatory bowel conditions, particularly ulcerative colitis, seeking therapies that promote mucosal healing and symptom relief.
- Obefazimod versus placebo for endoscopic improvement and remission
- ABTECT‑2 trial evaluating ABX464 in moderate to severe ulcerative colitis
The goal is to identify effective options that can achieve sustained disease control for patients with chronic digestive inflammation.
Nervous System Diseases
The site conducts research on neurological disorders such as migraine and agitation linked to Alzheimer’s disease, testing novel agents for symptom reduction.
- MEDI0618 repeat dosing to prevent episodic migraine headaches
- KarXT + KarX‑EC for agitation associated with Alzheimer’s disease
These investigations aim to provide safer, more effective ways to manage pain and behavioral symptoms that impact quality of life.
Skin and Connective Tissue Diseases
A dedicated trial evaluates advanced cell‑based therapy for patients with chronic, non‑healing venous leg ulcers, a condition that often resists conventional treatment.
- Topical allo‑APZ2‑CVU stem cell product compared with placebo for wound closure
The study’s purpose is to determine whether the investigational product can accelerate healing and reduce ulcer recurrence.
Mental Disorders
Research on mental disorders centers on agitation in Alzheimer’s disease, evaluating both safety and efficacy of a combined pharmacologic approach.
- Long‑term safety and tolerability of KarXT + KarX‑EC
- Efficacy measured by reduction in agitation scores using the CMAI‑IPA scale
These trials seek to offer clinicians new tools to manage behavioral challenges in dementia care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 91 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
- 1AstraZeneca AB8active
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International15trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Obudai Egeszseguegyi Centrum Kft.
lock Showing 1 of 125 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 91 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 7 | Unknown | 2023-11-07 | 2026-07-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.